Perspective Therapeutics Analyst Price Targets

Perspective Therapeutics Inc

CATXAMEX

Trade with Public

$2.19

0.020.92%

概要ニュース業績予想イベント目標株価財務センチメント株主構成比較株式レポート

Perspective Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Perspective Therapeutics (CATX).

Price Target Range — 13 Quarters

Analyst Consensus — 15 Analysts

14Buy

1Hold

Consensus RatingBuy# Analysts15Avg. Consensus PT$13

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 7, 2026	BTIG	Jeet Mukherjee	Maintained	Buy	$14
Sep 18, 2026	William Blair	Andy Hsieh	Initiate	Outperform	—
Sep 15, 2026	Wedbush	David Nierengarten	Maintained	Outperform	$11
Aug 19, 2026	BMO Capital	David Lebowitz	Initiate	Outperform	$11
Aug 14, 2026	B of A Securities	Alec Stranahan	PT Cut	Neutral	$6→$5
Aug 11, 2026	Piper Sandler	Biren Amin	PT Cut	Overweight	$16→$14
May 5, 2026	Wedbush	David Nierengarten	Maintained	Outperform	$11
Apr 20, 2026	Wedbush	David Nierengarten	Maintained	Outperform	$11
Mar 23, 2026	HC Wainwright & Co.	Robert Burns	PT Raise	Buy	$12→$13
Mar 18, 2026	B. Riley Securities	Yuan Zhi	PT Raise	Buy	$11→$13
Mar 18, 2026	UBS	David Dai	PT Raise	Buy	$7→$8
Mar 18, 2026	Wedbush	David Nierengarten	Maintained	Outperform	$11
Mar 17, 2026	RBC Capital	Leonid Timashev	PT Cut	Outperform	$18→$14
Mar 17, 2026	BTIG	Jeet Mukherjee	Maintained	Buy	$14
Feb 19, 2026	Piper Sandler	Biren Amin	Initiate	Overweight	$16
Jan 30, 2026	HC Wainwright & Co.	Robert Burns	PT Raise	Buy	$10→$12
Jan 30, 2026	Wedbush	David Nierengarten	Maintained	Outperform	$11
Jan 13, 2026	BTIG	Jeet Mukherjee	Maintained	Buy	$14
Nov 24, 2025	Truist Securities	Gregory Renza	Assumes	Buy	$8→$12
Nov 21, 2025	UBS	David Dai	PT Cut	Buy	$18→$7

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
BTIG Reiterates Buy on Perspective Therapeutics, Maintains $14 Price Target

BTIG analyst Jeet Mukherjee reiterates Perspective Therapeutics (AMEX:CATX) with a Buy and maintains $14 price target.

Benzinga Newsdesk

This $3 Biotech Could Be Worth $11.45, Analyst Says

William Blair initiates Perspective Therapeutics (NYSE: CATX) at Outperform, citing its strong radiopharmaceutical platform.

Vandana Singh

PRO
William Blair Initiates Coverage On Perspective Therapeutics with Outperform Rating

William Blair analyst Andy Hsieh initiates coverage on Perspective Therapeutics (AMEX:CATX) with a Outperform rating.

Benzinga Newsdesk

PRO
Wedbush Reiterates Outperform on Perspective Therapeutics, Maintains $11 Price Target

Wedbush analyst David Nierengarten reiterates Perspective Therapeutics (AMEX:CATX) with a Outperform and maintains $11 price target.

Benzinga Newsdesk

PRO
BMO Capital Initiates Coverage On Perspective Therapeutics with Outperform Rating, Announces Price Target of $11

BMO Capital analyst David Lebowitz initiates coverage on Perspective Therapeutics (AMEX:CATX) with a Outperform rating and announces Price Target of $11.

Benzinga Newsdesk

PRO
B of A Securities Maintains Neutral on Perspective Therapeutics, Lowers Price Target to $5

B of A Securities analyst Alec Stranahan maintains Perspective Therapeutics (AMEX:CATX) with a Neutral and lowers the price target from $6 to $5.

Benzinga Newsdesk

Perspective Therapeutics Inc

Perspective Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
BTIG Reiterates Buy on Perspective Therapeutics, Maintains $14 Price Target

This $3 Biotech Could Be Worth $11.45, Analyst Says

PRO
William Blair Initiates Coverage On Perspective Therapeutics with Outperform Rating

PRO
Wedbush Reiterates Outperform on Perspective Therapeutics, Maintains $11 Price Target

PRO
BMO Capital Initiates Coverage On Perspective Therapeutics with Outperform Rating, Announces Price Target of $11

PRO
B of A Securities Maintains Neutral on Perspective Therapeutics, Lowers Price Target to $5

ニュース

パートナーシップ

ベンジンガ・グローバル

Perspective Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
BTIG Reiterates Buy on Perspective Therapeutics, Maintains $14 Price Target

This $3 Biotech Could Be Worth $11.45, Analyst Says

PRO
William Blair Initiates Coverage On Perspective Therapeutics with Outperform Rating

PRO
Wedbush Reiterates Outperform on Perspective Therapeutics, Maintains $11 Price Target

PRO
BMO Capital Initiates Coverage On Perspective Therapeutics with Outperform Rating, Announces Price Target of $11

PRO
B of A Securities Maintains Neutral on Perspective Therapeutics, Lowers Price Target to $5

People Also Watch

People Also Watch

Perspective Therapeutics Inc

Perspective Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROBTIG Reiterates Buy on Perspective Therapeutics, Maintains $14 Price Target

This $3 Biotech Could Be Worth $11.45, Analyst Says

PROWilliam Blair Initiates Coverage On Perspective Therapeutics with Outperform Rating

PROWedbush Reiterates Outperform on Perspective Therapeutics, Maintains $11 Price Target

PROBMO Capital Initiates Coverage On Perspective Therapeutics with Outperform Rating, Announces Price Target of $11

PROB of A Securities Maintains Neutral on Perspective Therapeutics, Lowers Price Target to $5

ニュース

パートナーシップ

ベンジンガ・グローバル

Perspective Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROBTIG Reiterates Buy on Perspective Therapeutics, Maintains $14 Price Target

This $3 Biotech Could Be Worth $11.45, Analyst Says

PROWilliam Blair Initiates Coverage On Perspective Therapeutics with Outperform Rating

PROWedbush Reiterates Outperform on Perspective Therapeutics, Maintains $11 Price Target

PROBMO Capital Initiates Coverage On Perspective Therapeutics with Outperform Rating, Announces Price Target of $11

PROB of A Securities Maintains Neutral on Perspective Therapeutics, Lowers Price Target to $5

People Also Watch

People Also Watch

PRO
BTIG Reiterates Buy on Perspective Therapeutics, Maintains $14 Price Target

PRO
William Blair Initiates Coverage On Perspective Therapeutics with Outperform Rating

PRO
Wedbush Reiterates Outperform on Perspective Therapeutics, Maintains $11 Price Target

PRO
BMO Capital Initiates Coverage On Perspective Therapeutics with Outperform Rating, Announces Price Target of $11

PRO
B of A Securities Maintains Neutral on Perspective Therapeutics, Lowers Price Target to $5

PRO
BTIG Reiterates Buy on Perspective Therapeutics, Maintains $14 Price Target

PRO
William Blair Initiates Coverage On Perspective Therapeutics with Outperform Rating

PRO
Wedbush Reiterates Outperform on Perspective Therapeutics, Maintains $11 Price Target

PRO
BMO Capital Initiates Coverage On Perspective Therapeutics with Outperform Rating, Announces Price Target of $11

PRO
B of A Securities Maintains Neutral on Perspective Therapeutics, Lowers Price Target to $5